Search Results - "Gerritsen, Winald R."

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond by Bol, Kalijn F, Schreibelt, Gerty, Gerritsen, Winald R, de Vries, I Jolanda M, Figdor, Carl G

“…Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor antigens and was first…”
Get full text

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors by Fizazi, Karim, Drake, Charles G., Beer, Tomasz M., Kwon, Eugene D., Scher, Howard I., Gerritsen, Winald R., Bossi, Alberto, den Eertwegh, Alfons J.M. van, Krainer, Michael, Houede, Nadine, Santos, Ricardo, Mahammedi, Hakim, Ng, Siobhan, Danielli, Riccardo, Franke, Fabio A., Sundar, Santhanam, Agarwal, Neeraj, Bergman, André M., Ciuleanu, Tudor E., Korbenfeld, Ernesto, Sengeløv, Lisa, Hansen, Steinbjorn, McHenry, M. Brent, Chen, Allen, Logothetis, Christopher

“…The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate…”
Get full text

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy by Ryan, Charles J, Smith, Matthew R, de Bono, Johann S, Molina, Arturo, Logothetis, Christopher J, de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, Josep M, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A, Basch, Ethan, Small, Eric J, Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D, Suttmann, Henrik, Gerritsen, Winald R, Flaig, Thomas W, George, Daniel J, Yu, Evan Y, Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S, Taplin, Mary-Ellen, Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I, Rathkopf, Dana E

“…Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant…”
Get full text

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time by van Willigen, Wouter W, Bloemendal, Martine, Gerritsen, Winald R, Schreibelt, Gerty, de Vries, I Jolanda M, Bol, Kalijn F

“…Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many different tumor types. Superior overall survival over chemotherapy…”
Get full text

Blood platelets contain tumor-derived RNA biomarkers by Nilsson, R. Jonas A., Balaj, Leonora, Hulleman, Esther, van Rijn, Sjoerd, Pegtel, D. Michiel, Walraven, Maudy, Widmark, Anders, Gerritsen, Winald R., Verheul, Henk M., Vandertop, W. Peter, Noske, David P., Skog, Johan, Würdinger, Thomas

“…Diagnostic platforms providing biomarkers that are highly predictive for diagnosing, monitoring, and stratifying cancer patients are key instruments in the…”
Get full text

mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm by Willemsen, Annelieke E.C.A.B., Grutters, Jan C., Gerritsen, Winald R., van Erp, Nielka P., van Herpen, Carla M.L., Tol, Jolien

“…Mammalian target of rapamycin inhibitors (mTORi) have clinically significant activity against various malignancies, such as renal cell carcinoma and breast…”
Get full text

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial by van den Eertwegh, Alfons JM, MD, Versluis, Jurjen, MD, van den Berg, H Pieter, MD, Santegoets, Saskia JAM, PhD, van Moorselaar, R Jeroen A, Prof, van der Sluis, Tim M, MD, Gall, Helen E, MNAP, Harding, Thomas C, MD, Jooss, Karin, PhD, Lowy, Israel, MD, Pinedo, Herbert M, Prof, Scheper, Rik J, Prof, Stam, Anita GM, BSc, von Blomberg, B Mary E, PhD, de Gruijl, Tanja D, PhD, Hege, Kristen, MD, Sacks, Natalie, MD, Gerritsen, Winald R, Prof

“…Summary Background The granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) has antitumour activity…”
Get full text

Immune Checkpoint Inhibitor–related Guillain-Barré Syndrome: A Case Series and Review of the Literature by Janssen, Jorien B.E., Leow, Theresa Y.S., Herbschleb, Karin H., Gijtenbeek, Johanna M.M., Boers-Sonderen, Marye J., Gerritsen, Winald R., Westdorp, Harm

“…Immune checkpoint inhibitors (ICIs) have been approved for the treatment of various malignancies with promising clinical outcomes. Treatment can, however, be…”
Get full text

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity by van Wilpe, Sandra, Tolmeijer, Sofie H., Koornstra, Rutger H. T., de Vries, I. Jolanda M., Gerritsen, Winald R., Ligtenberg, Marjolijn, Mehra, Niven

“…Homologous recombination repair deficiency (HRD) can be observed in virtually all cancer types. Although HRD sensitizes tumors to DNA-damaging chemotherapy and…”
Get full text

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol by Creemers, Jeroen H A, Pawlitzky, Inka, Grosios, Konstantina, Gileadi, Uzi, Middleton, Mark R, Gerritsen, Winald R, Mehra, Niven, Rivoltini, Licia, Walters, Ian, Figdor, Carl G, Ottevanger, Petronella B, de Vries, I Jolanda M

“…IntroductionThe undiminished need for more effective cancer treatments stimulates the development of novel cancer immunotherapy candidates. The archetypical…”
Get full text

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer by Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., Gerritsen, Winald R.

“…BackgroundClinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the…”
Get full text

Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients by Bloemendal, Martine, Bol, Kalijn F., Boudewijns, Steve, Gorris, Mark A.J., de Wilt, Johannes H.W., Croockewit, Sandra A.J., van Rossum, Michelle M., de Goede, Anna L., Petry, Katja, Koornstra, Rutger H.T., Figdor, Carl, Gerritsen, Winald R., Schreibelt, Gerty, de Vries, I. Jolanda M.

“…We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally…”
Get full text

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer by Kuppen, Malou Cp, Westgeest, Hans M, van der Doelen, Maarten J, van den Eertwegh, Alphonsus Jm, Coenen, Jules Llm, Aben, Katja Kh, van den Bergh, Alphons Cm, Bergman, Andries M, den Bosch, Joan van, Celik, Filiz, Hendriks, Mathijs P, Lavalaye, Jules, der Meer, Saskia van, Polee, Marco B, Somford, Diederik M, van Oort, Inge M, Uyl-de Groot, Carin A, Gerritsen, Winald R

“…Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of…”
Get full text

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype by van Wilpe, Sandra, Simnica, Donjetë, Slootbeek, Peter, van Ee, Thomas, Pamidimarri Naga, Samhita, Gorris, Mark A. J., van der Woude, Lieke L., Sultan, Shabaz, Koornstra, Rutger H. T., van Oort, Inge M., Gerritsen, Winald R., Kroeze, Leonie I., Simons, Michiel, van Leenders, Geert J. L. H., Binder, Mascha, de Vries, I. Jolanda M., Mehra, Niven

“…Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that…”
Get full text

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer by van Wilpe, Sandra, Gorris, Mark A J, van der Woude, Lieke L, Sultan, Shabaz, Koornstra, Rutger H T, van der Heijden, Antoine G, Gerritsen, Winald R, Simons, Michiel, de Vries, I Jolanda M, Mehra, Niven

“…Checkpoint inhibitors targeting PD-(L)1 induce objective responses in 20% of patients with metastatic urothelial cancer (UC). CD8 T cell infiltration has been…”
Get full text

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial by Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., van Gemert, Willemijn A., de Groot, Michel, Westdorp, Harm, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James

“…Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177 Lu-PSMA is an effective…”
Get full text

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens by Westdorp, Harm, Sköld, Annette E, Snijer, Berit A, Franik, Sebastian, Mulder, Sasja F, Major, Pierre P, Foley, Ronan, Gerritsen, Winald R, de Vries, I Jolanda M

“…Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic…”
Get full text

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms by Quinn, David I., M.D., Ph.D, Shore, Neal D., M.D, Egawa, Shin, M.D., Ph.D, Gerritsen, Winald R., M.D., Ph.D, Fizazi, Karim, M.D., Ph.D

“…Abstract Background The approval of sipuleucel-T in conjunction with data from other immunotherapeutic trials for prostate cancer and other solid tumors…”
Get full text

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery by Creemers, Jeroen H A, Lesterhuis, W Joost, Mehra, Niven, Gerritsen, Winald R, Figdor, Carl G, de Vries, I Jolanda M, Textor, Johannes

“…BackgroundPredicting treatment response or survival of cancer patients remains challenging in immuno-oncology. Efforts to overcome these challenges focus,…”
Get full text

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination by van Willigen, Wouter W., Bloemendal, Martine, Boers-Sonderen, Marye J., de Groot, Jan Willem B., Koornstra, Rutger H.T., van der Veldt, Astrid A.M., Haanen, John B. A. G., Boudewijns, Steve, Schreibelt, Gerty, Gerritsen, Winald R., de Vries, I. Jolanda M., Bol, Kalijn F.

“…Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality…”
Get full text